Results 71 to 80 of about 119,167 (297)

Neuroprotective effects of lixisenatide against propagation of α-synuclein pathology in Parkinson’s disease

open access: yesNeural Regeneration Research
Glucagon-like peptide-1 receptor agonists, originally developed for the treatment of type 2 diabetes mellitus, have been suggested as a potential disease-modifying treatment for Parkinson’s disease.
Shangqi Sun   +10 more
doaj   +1 more source

Gut Health in Ostriches (Struthio camelus): Insights Into Intestinal Structure, Functions, Microbiome, and Improvement Strategies

open access: yesAnimal Research and One Health, EarlyView.
Our paper systematically reviews the intestinal structure, function, and microbiota of ostriches, along with strategies for improving their gut health. We analyze how these factors collectively influence intestinal homeostasis and ostrich welfare, emphasizing probiotics as a promising intervention to enhance gut health, boost population well‐being, and
Zi‐Qun Zhang   +6 more
wiley   +1 more source

Effects of Exenatide in a Morbidly Obese Patient with Type 2 Diabetes [PDF]

open access: yes, 2014
INTRODUCTION: The effect of exenatide in weight loss has been reported. Presented here is a case of a morbidly obese patient with type 2 diabetes using exenatide who dramatically lost her body weight in a year and experienced improved glycemic control ...
Mitsuhiko Noda, Miyako Kishimoto
core   +1 more source

Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial

open access: yesArthritis &Rheumatology, EarlyView.
Objective Overweight or obesity is prevalent in 72% to 82% of individuals with psoriatic arthritis (PsA). We assessed the efficacy and safety of ixekizumab (IXE) concomitantly administered with tirzepatide (TZP) compared with IXE alone in adult participants with active PsA and overweight with at least one weight‐related comorbidity or obesity.
Joseph F. Merola   +14 more
wiley   +1 more source

Compounded glucagon-like peptide-1 receptor agonists for weight loss: the direct-to-consumer market in Colorado

open access: yesJournal of Pharmaceutical Policy and Practice
Background High prices and other access barriers have contributed to the rise of a market for compounded glucagon-like peptide-1 receptor agonists for weight loss in the United States. This market has not been systematically studied. We conducted a pilot
Michael J. DiStefano   +4 more
doaj   +1 more source

Glucagon-Like Peptide 1: A Predictor of Type 2 Diabetes?

open access: yesJournal of Diabetes Research, 2017
Background. The incretin effect is impaired in patients with type 2 diabetes. Aim. To assess the relation between the incretin hormone GLP-1 and the prediabetic subtypes: impaired fasting glucose (IFG), impaired glucose tolerance (IGT), and the combined ...
Matthias Ploug Larsen   +1 more
doaj   +1 more source

Liraglutide in the management of type 2 diabetes [PDF]

open access: yes, 2010
Estela Wajcberg, Amatur AmarahPremier Nephrology and Hypertension, Internal Medicine Department, Trinitas Regional Medical Center, Elizabeth, New Jersey, USAAbstract: The pathophysiology of type 2 diabetes has been attributed to the classic triad of ...
Estela Wajcberg, Amatur Amarah
core   +3 more sources

Beyond right or wrong: How partial credit scoring on multiple‐choice questions improves student performance and assessment perceptions

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims In this study, we examined the effects of assigning partial credit to selected answer choices on student performance and perceptions in a pharmacology course using Type A multiple‐choice questions (MCQs). Methods Partial credit scoring was incorporated into quizzes and exams in a 10‐week pharmacology course for postbaccalaureate premedical ...
Stephen D. Schneid   +2 more
wiley   +1 more source

Continuous glucose monitoring guides glucagon-like peptide 1-based therapy use and optimization in people with type 2 diabetes

open access: yesJournal of Family Medicine and Primary Care
Type 2 diabetes (T2D) is a large and growing epidemic. Importantly, new technologies and pharmaceutical options are improving the management of T2D. Continuous glucose monitoring (CGM) systems have advanced glucose-sensing technology, which has made it ...
Rita Parsiani   +4 more
doaj   +1 more source

Hepatocyte-specific HIF-1α ablation improves obesity-induced glucose intolerance by reducing first-pass GLP-1 degradation. [PDF]

open access: yes, 2019
The decrease in incretin effects is an important etiologic component of type 2 diabetes with unknown mechanisms. In an attempt to understand obesity-induced changes in liver oxygen homeostasis, we found that liver HIF-1α expression was increased mainly ...
Bandyopadhyay, Guatam K   +3 more
core  

Home - About - Disclaimer - Privacy